216 related articles for article (PubMed ID: 17001009)
1. Identification of class I MHC-associated phosphopeptides as targets for cancer immunotherapy.
Zarling AL; Polefrone JM; Evans AM; Mikesh LM; Shabanowitz J; Lewis ST; Engelhard VH; Hunt DF
Proc Natl Acad Sci U S A; 2006 Oct; 103(40):14889-94. PubMed ID: 17001009
[TBL] [Abstract][Full Text] [Related]
2. Tumors reveal their secrets to cytotoxic T cells.
Williamson NA; Rossjohn J; Purcell AW
Proc Natl Acad Sci U S A; 2006 Oct; 103(40):14649-50. PubMed ID: 17005729
[No Abstract] [Full Text] [Related]
3. MHC-restricted phosphopeptides from insulin receptor substrate-2 and CDC25b offer broad-based immunotherapeutic agents for cancer.
Zarling AL; Obeng RC; Desch AN; Pinczewski J; Cummings KL; Deacon DH; Conaway M; Slingluff CL; Engelhard VH
Cancer Res; 2014 Dec; 74(23):6784-95. PubMed ID: 25297629
[TBL] [Abstract][Full Text] [Related]
4. MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma.
Engelhard VH; Obeng RC; Cummings KL; Petroni GR; Ambakhutwala AL; Chianese-Bullock KA; Smith KT; Lulu A; Varhegyi N; Smolkin ME; Myers P; Mahoney KE; Shabanowitz J; Buettner N; Hall EH; Haden K; Cobbold M; Hunt DF; Weiss G; Gaughan E; Slingluff CL
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32385144
[TBL] [Abstract][Full Text] [Related]
5. Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy.
Depontieu FR; Qian J; Zarling AL; McMiller TL; Salay TM; Norris A; English AM; Shabanowitz J; Engelhard VH; Hunt DF; Topalian SL
Proc Natl Acad Sci U S A; 2009 Jul; 106(29):12073-8. PubMed ID: 19581576
[TBL] [Abstract][Full Text] [Related]
6. Phosphorylation-dependent interaction between antigenic peptides and MHC class I: a molecular basis for the presentation of transformed self.
Mohammed F; Cobbold M; Zarling AL; Salim M; Barrett-Wilt GA; Shabanowitz J; Hunt DF; Engelhard VH; Willcox BE
Nat Immunol; 2008 Nov; 9(11):1236-43. PubMed ID: 18836451
[TBL] [Abstract][Full Text] [Related]
7. Structural basis for the presentation of tumor-associated MHC class II-restricted phosphopeptides to CD4+ T cells.
Li Y; Depontieu FR; Sidney J; Salay TM; Engelhard VH; Hunt DF; Sette A; Topalian SL; Mariuzza RA
J Mol Biol; 2010 Jun; 399(4):596-603. PubMed ID: 20417641
[TBL] [Abstract][Full Text] [Related]
8. Characterization of HLA-A2-restricted HPV-16 E7-specific CD8(+) T-cell immune responses induced by DNA vaccines in HLA-A2 transgenic mice.
Peng S; Trimble C; He L; Tsai YC; Lin CT; Boyd DA; Pardoll D; Hung CF; Wu TC
Gene Ther; 2006 Jan; 13(1):67-77. PubMed ID: 16107858
[TBL] [Abstract][Full Text] [Related]
9. Small cell lung carcinomas express shared and private tumor antigens presented by HLA-A1 or HLA-A2.
Yamazaki K; Spruill G; Rhoderick J; Spielman J; Savaraj N; Podack ER
Cancer Res; 1999 Sep; 59(18):4642-50. PubMed ID: 10493519
[TBL] [Abstract][Full Text] [Related]
10. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles.
Kawakami Y; Robbins PF; Wang X; Tupesis JP; Parkhurst MR; Kang X; Sakaguchi K; Appella E; Rosenberg SA
J Immunol; 1998 Dec; 161(12):6985-92. PubMed ID: 9862734
[TBL] [Abstract][Full Text] [Related]
11. Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations.
Abrams SI; Khleif SN; Bergmann-Leitner ES; Kantor JA; Chung Y; Hamilton JM; Schlom J
Cell Immunol; 1997 Dec; 182(2):137-51. PubMed ID: 9514698
[TBL] [Abstract][Full Text] [Related]
12. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.
Bondurant KL; Crew MD; Santin AD; O'Brien TJ; Cannon MJ
Clin Cancer Res; 2005 May; 11(9):3446-54. PubMed ID: 15867247
[TBL] [Abstract][Full Text] [Related]
13. Increased frequencies of CD8+ T lymphocytes recognizing wild-type p53-derived epitopes in peripheral blood correlate with presence of epitope loss tumor variants in patients with hepatocellular carcinoma.
Cicinnati VR; Zhang X; Yu Z; Ferencik S; Schmitz KJ; Dworacki G; Kaczmarek E; Oldhafer K; Frilling A; Baba HA; Schmid KW; Grosse-Wilde H; Broelsch CE; DeLeo AB; Gerken G; Beckebaum S
Int J Cancer; 2006 Dec; 119(12):2851-60. PubMed ID: 16998881
[TBL] [Abstract][Full Text] [Related]
14. Identification of naturally processed human ovarian peptides recognized by tumor-associated CD8+ cytotoxic T lymphocytes.
Fisk B; Anderson BW; Gravitt KR; O'Brian CA; Kudelka AP; Murray JL; Wharton JT; Ioannides CG
Cancer Res; 1997 Jan; 57(1):87-93. PubMed ID: 8988046
[TBL] [Abstract][Full Text] [Related]
15. Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma.
Hundemer M; Schmidt S; Condomines M; Lupu A; Hose D; Moos M; Cremer F; Kleist C; Terness P; Belle S; Ho AD; Goldschmidt H; Klein B; Christensen O
Exp Hematol; 2006 Apr; 34(4):486-96. PubMed ID: 16569595
[TBL] [Abstract][Full Text] [Related]
16. Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51.
Jäger E; Karbach J; Gnjatic S; Jäger D; Maeurer M; Atmaca A; Arand M; Skipper J; Stockert E; Chen YT; Old LJ; Knuth A
Cancer Immun; 2002 Sep; 2():12. PubMed ID: 12747757
[TBL] [Abstract][Full Text] [Related]
17. The landscape of MHC-presented phosphopeptides yields actionable shared tumor antigens for cancer immunotherapy across multiple HLA alleles.
Molvi Z; Klatt MG; Dao T; Urraca J; Scheinberg DA; O'Reilly RJ
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37775115
[TBL] [Abstract][Full Text] [Related]
18. Tumor escape from immune recognition: loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 6.
Maeurer MJ; Gollin SM; Storkus WJ; Swaney W; Karbach J; Martin D; Castelli C; Salter R; Knuth A; Lotze MT
Clin Cancer Res; 1996 Apr; 2(4):641-52. PubMed ID: 9816214
[TBL] [Abstract][Full Text] [Related]
19. Phosphorylated peptides can be transported by TAP molecules, presented by class I MHC molecules, and recognized by phosphopeptide-specific CTL.
Andersen MH; Bonfill JE; Neisig A; Arsequell G; Sondergaard I; Valencia G; Neefjes J; Zeuthen J; Elliott T; Haurum JS
J Immunol; 1999 Oct; 163(7):3812-8. PubMed ID: 10490979
[TBL] [Abstract][Full Text] [Related]
20. MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia.
Cobbold M; De La Peña H; Norris A; Polefrone JM; Qian J; English AM; Cummings KL; Penny S; Turner JE; Cottine J; Abelin JG; Malaker SA; Zarling AL; Huang HW; Goodyear O; Freeman SD; Shabanowitz J; Pratt G; Craddock C; Williams ME; Hunt DF; Engelhard VH
Sci Transl Med; 2013 Sep; 5(203):203ra125. PubMed ID: 24048523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
